How has MoonLake Immunotherapeutics's cumulative cost basis changed year-over-year?

MoonLake Immunotherapeutics's cumulative cost basis decreased by 71.3% year-over-year, from $205.91M to $59.07M.

MoonLake Immunotherapeutics MLTX Cumulative Cost Basis

Cumulative Cost Basis at other companies

Oruka Therapeutics, Inc.ORKA

——

Nektar TherapeuticsNKTR

——

Aurinia PharmaceuticalsAUPH

——

Arcutis Biotherapeutics, Inc.ARQT

——

ImmunityBio, Inc.IBRX

——

Johnson & JohnsonJNJ

——

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's cumulative cost basis?: MoonLake Immunotherapeutics (MLTX) reported cumulative cost basis of $59.07M in Q1 2026.
How has MoonLake Immunotherapeutics's cumulative cost basis changed year-over-year?: MoonLake Immunotherapeutics's cumulative cost basis decreased by 71.3% year-over-year, from $205.91M to $59.07M.